Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits

Table 6 Health state utilities for HCV patients achieving SVR

Method	Study	Value		Difference
Method	Study	SVR	Non-response/relapse	Difference
EQ5D	Thein et al. 2005 [93]	0.83	―	―
	Chong et al. 2003 [95]	0.83	0.76^c	0.07
	Van Rooijen et al. 2011 [99]	0.84	0.70	0.14
SF-36	Thein et al. 2005 [93]	0.74–0.90	0.70–0.86^b	0.04–0.05
SF-6D	Hsu et al. 2012 [103]	0.71	0.66^c	0.05
	John-Baptiste et al. 2009 [18]	0.71	0.65	0.06
HUI3	Thein et al. 2005 [93]	0.77	―	―
	John-Baptiste et al. 2009 [18]	0.70	0.58	0.12
	Hsu et al. 2012 [103]	0.70	0.57^c	0.13
HUI	Chong et al. 2003 [95]	0.77	0.73^c	0.04
TTO	John-Baptiste et al. 2009 [18]	0.89	0.84	0.05
	Hsu et al. 2012 [103]	0.88	0.80^c	0.08
SG	Thein et al. 2005 [93]	0.86	―	―
	Chong et al. 2003 [95]	0.86	0.79^c	0.08
VAS	Thein et al. 2005 [93]	0.74	―	―
	Chong et al. 2003 [95]	0.74	0.70^c	0.04
Not stated	Liu et al. 2012 [104]	0.933–1.00^a	―	―
	Chhatwal et al. 2013 [105]	1.00	―	―

HUI3, Health Utilities Index Mark 3; SF-36, Medical Outcomes Study 36-item Short-Form Health Survey; SG, standard gamble; TTO, time trade off; VAS, visual analog scale.
^aAge-specific quality of life weight.
^bUntreated.
^cPatients with mild/moderate HCV or chronic infection.

ISSN: 1471-2334